Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co. It is grouped under the following drug class(es): Thiazolidinediones. The directory classifies it as a discontinued API with a synthetic source/manufacturing origin. Other names for this substance include CS-011. Its PubChem CID is 3055168.
Rivoglitazone
| CAS No | 185428-18-6 |
|---|---|
| Molecular Formula | C20H19N3O4S |
| Molecular Weight | 397.4 g/mol |
| Synonyms | 5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes. It is being developed by Daiichi Sankyo Co. It is grouped under the following drug class(es): Thiazolidinediones.
The listed CAS number is 185428-18-6.
The listed molecular formula is C20H19N3O4S.
The listed molecular weight is 397.4 g/mol.
5-[[4-[(6-methoxy-1-methylbenzimidazol-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione.
The source lists CS-011.